TRANSFORMING GROWTH FACTOR - BETA MEDIATES EFFECTS OF HYPOXIA IN NEWBORN LUNG
TRANSFORMING GROWTH FACTOR - BETA MEDIATES EFFECTS OF HYPOXIA IN NEWBORN LUNG
批准号:
8286350
负责人:
Namasivayam Ambalavanan
金额:
$35.89万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-15 至 2014-06-30
关键词:
AirAirway ResistanceAlveolarAttenuatedBindingBiologicalBirthBronchopulmonary DysplasiaCaringCause of DeathChronicCollagenDataDevelopmentDiseaseDominant-Negative MutationEndothelin-1Extracellular Matrix ProteinsFibroblastsGrowth FactorHamman-Rich syndromeHypoxiaIncidenceIntegrinsKnockout MiceKnowledgeLaboratoriesLeadLungLung ComplianceMatrix MetalloproteinasesMechanicsMediatingMediator of activation proteinMembrane GlycoproteinsMorbidity - disease rateMusMyofibroblastNeonatalNewborn InfantPathogenesisPathway interactionsPeptidesPerinatalPersistent Fetal Circulation SyndromePhenotypePremature InfantProductionProteinsPulmonary HypertensionReactive Oxygen SpeciesResistanceRoleSignal InductionSignal PathwaySignal TransductionSmooth Muscle Actin Staining MethodSmooth Muscle MyocytesStructure of parenchyma of lungTestingTherapeuticThrombospondin 1Transforming Growth Factor betaTransgenic MiceVascular remodelingWild Type Mousearterial remodelingin vitro Modelin vivo Modelinhibitor/antagonistinterstitiallung developmentneutralizing antibodynovelnovel therapeuticspersistent pulmonary hypertensionpreventreceptorresearch study
中文摘要
描述(申请人提供):慢性低氧导致发育中的肺异常的肺动脉重塑(PAR)和肺泡发育抑制(IAD)。转化生长因子-β(TGF-β)是一种多肽生长因子,是肺发育和血管重塑的关键调节因子,可能是PAR和IAD发病机制中的重要介质。转化生长因子-β是作为一种非活性前体合成的,而转化生长因子-β的激活是产生生物效应的关键步骤。肺中表达细胞表面糖蛋白Thy-1的成纤维细胞抑制了转化生长因子-β的激活。我们最近发现,由于可诱导的显性阴性的转化生长因子-2受体(DN2RII)而导致转化生长因子-1信号转导中断的新生小鼠可减弱IAD和PAR,表明转化生长因子-1信号在IAD和PAR中起重要作用。我们已经证明,在新生小鼠中,低氧降低Thy-1,增加活性的转化生长因子-1,这表明低氧诱导的Thy-1的减少可能允许增加转化生长因子-1的活性。我们的实验室进行了新的观察,发现Thy-1基因缺失的小鼠存在IAD,并增加了磷酸化Smad2,(-平滑肌肌动蛋白、间质胶原、组织肺阻力(但正常气道阻力)和肺顺应性降低,表明发育中的肺组织中Thy-1缺失会导致类似于支气管肺发育不良(BPD)的肺表型。我们的初步数据表明,转化生长因子-β的合成可能受已知的PAR的介导物-内皮素-1(ET-1)的调节。该项目的目的是确定在肺发育过程中低氧暴露导致转化生长因子-β活化增加以及随后的PAR和IAD的机制。具体目标1将检验这一假设,即转化生长因子-1信号在低氧诱导的PAR和IAD中是必需的。具体目标2将评估Thy-1在转化生长因子-1激活中的机制作用以及在有或没有缺氧的情况下IAD的发病机制。特定目标3将检验低氧诱导ET-1增加刺激转化生长因子-1合成和激活这一特定假设。将使用体内模型(新生小鼠从出生起暴露在低氧或空气中2周)和体外模型(新生小鼠的肺动脉平滑肌细胞和成纤维细胞)的垂直整合方法。目前可用的转基因小鼠(Thy-1缺失,DN2RII,(6整合素缺失),以及野生型小鼠将被用来表征关键的信号通路。PAR导致新生儿持续性肺动脉高压(PPHN),IAD和PAR均见于BPD。尽管新生儿护理取得了进步,但PPHN和BPD的发生率仍然很高,新的范例对于开发新的治疗策略至关重要。这项提案中概述的实验将增加我们对围产期正常和异常肺动脉重塑和肺泡发育的机制的了解。至少,这些研究将确定转化生长因子-(作为低氧诱导的IAD和PAR的关键调节因子)的作用。这些实验还将确定受低氧调控的转化生长因子-(信号通路)的成分,以及低氧条件下的转化生长因子-()激活剂。项目简介:新生儿死亡和发病的两个主要原因是新生儿持续性肺动脉高压(PPHN)和支气管肺发育不良(BPD),其特征是异常的肺动脉增厚、肺动脉高压和肺泡发育受阻。转化生长因子-β是一种对正常肺发育至关重要的蛋白质,过度激活可能会导致PPHN和BPD中出现的肺发育异常。这项建议将确定转化生长因子-β在肺发育异常中的作用以及转化生长因子-β被激活的机制,并可能导致PPHN和BPD的新治疗方案的开发。
英文摘要
DESCRIPTION (provided by applicant): Chronic hypoxia leads to abnormal pulmonary arterial remodeling (PAR) and inhibition of alveolar development (IAD) in the developing lung. Transforming growth factor-beta (TGF-(), a peptide growth factor that is a key regulator of lung development and vascular remodeling, may be a crucial mediator in the pathogenesis of PAR and IAD. TGF-( is synthesized as an inactive precursor, and activation of TGF-( is the critical step necessary to elicit biological effects. TGF-( activation is inhibited by fibroblasts in the lung which express the cell surface glycoprotein Thy-1. We have recently shown that newborn mice with disruption of TGF-( signaling due to inducible dominant negative TGF-( type II receptors (DN2RII) have attenuated IAD and PAR, indicating that TGF-( signaling is important in IAD and PAR. We have shown that hypoxia reduces Thy-1 and increases active TGF-( in newborn mice, suggesting that hypoxia-induced decreases in Thy-1 may permit increased TGF-( activation. Our laboratory has made the novel observations that Thy-1 null mice have IAD and increased phospho-Smad2, (-smooth muscle actin, interstitial collagen, tissue lung resistance (but normal airway resistance), and decreased lung compliance, demonstrating that absence of Thy-1 in the developing lung leads to a lung phenotype similar to bronchopulmonary dysplasia (BPD). Our preliminary data indicate that TGF-( synthesis may be regulated by endothelin-1 (ET-1), a known mediator of PAR. The objective of this project is to determine the mechanisms by which hypoxic exposure during lung development leads to increased TGF-( activation and subsequent PAR and IAD. Specific Aim 1 will test the hypothesis that TGF-( signaling is necessary for hypoxia-induced PAR and IAD. Specific Aim 2 will assess the mechanistic role of Thy-1 in TGF-( activation and the pathogenesis of IAD in the presence or absence of hypoxia. Specific Aim 3 will test the specific hypothesis that hypoxia-induced increases in ET-1 stimulate TGF-( synthesis and activation. A vertically-integrated approach, with in vivo models (newborn mice exposed to hypoxia or air for 2 weeks from birth) and in vitro models (neonatal murine pulmonary arterial smooth muscle cells and fibroblasts) will be used. Currently available transgenic mice (Thy-1 null, DN2RII, (6 integrin null), in addition to wild-type mice will be used to characterize the critical signaling pathways. PAR contributes to persistent pulmonary hypertension of the newborn (PPHN), and both IAD and PAR are seen in BPD. The incidence of PPHN and BPD remains high despite advances in neonatal care, and new paradigms are essential for the development of novel therapeutic strategies. The experiments outlined in this proposal will increase our knowledge of the mechanisms responsible for normal and abnormal pulmonary arterial remodeling and alveolar development in the perinatal period. At a minimum, these studies will determine the role of TGF-( as a key regulator of hypoxia-induced IAD and PAR. These experiments will also identify the components of TGF-( signaling pathway regulated by hypoxia, and TGF-( activators under hypoxic conditions. PROJECT NARRATIVE: Two major causes of death and morbidity in newborn infants are persistent pulmonary hypertension of the newborn (PPHN) and bronchopulmonary dysplasia (BPD), which are characterized by abnormal pulmonary arterial thickening, pulmonary hypertension, and inhibition of alveolar development. Excessive activation of transforming growth factor-beta, a protein that is important in normal lung development, may lead to the abnormal lung development that is seen in PPHN and BPD. This proposal will determine the role of transforming growth factor-beta in abnormal lung development and the mechanisms by which transforming growth factor-beta becomes activated, and may lead to the development of new treatment options for PPHN and BPD.
期刊论文(14)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Evaluation of a pumpless lung assist device in hypoxia-induced pulmonary hypertension in juvenile piglets.
无泵肺辅助装置对幼年仔猪缺氧引起的肺动脉高压的评估。
DOI:
10.1203/pdr.0b013e3181bbc7ec
发表时间:
2009
期刊:
Pediatric research
影响因子:
3.6
作者:
[El-Ferzli,GeorgeT, Philips3rd,JosephB, Bulger,Arlene, Ambalavanan,Namasivayam]
通讯作者:
Ambalavanan,Namasivayam
DOI:
10.1371/journal.pone.0070196
发表时间:
2013
期刊:
PloS one
影响因子:
3.7
作者:
[Harris WT, Kelly DR, Zhou Y, Wang D, MacEwen M, Hagood JS, Clancy JP, Ambalavanan N, Sorscher EJ]
通讯作者:
Sorscher EJ
A pumpless lung assist device reduces mechanical ventilation-induced lung injury in juvenile piglets.
无泵肺辅助装置可减少仔猪机械通气引起的肺损伤。
DOI:
10.1203/pdr.0b013e3181bbbf7a
发表时间:
2009
期刊:
Pediatric research
影响因子:
3.6
作者:
[El-Ferzli,GeorgeT, Philips3rd,JosephB, Bulger,Arlene, Ambalavanan,Namasivayam]
通讯作者:
Ambalavanan,Namasivayam
DOI:
10.1165/rcmb.2013-0164oc
发表时间:
2013-12
期刊:
American journal of respiratory cell and molecular biology
影响因子:
6.4
作者:
[R. Xiao;Z. Perveen;R. Rouse;Viviana Le Donne;D. Paulsen;N. Ambalavanan;A. Penn]
通讯作者:
R. Xiao;Z. Perveen;R. Rouse;Viviana Le Donne;D. Paulsen;N. Ambalavanan;A. Penn
DOI:
10.1371/journal.pone.0045164
发表时间:
2012
期刊:
PloS one
影响因子:
3.7
作者:
[El-Ferzli GT, Dreher M, Patel RP, Ambalavanan N]
通讯作者:
Ambalavanan N
Let-7b in BPD
-
批准号:10655734
-
项目类别:
-
资助金额:$55.44万
-
财政年份:2023
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Prapela® SVS incubator pad: A cost-effective stochastic vibrotactile device to improve the clinical course of infants with apnea of prematurity.
-
批准号:10576754
-
项目类别:
-
资助金额:$50.02万
-
财政年份:2023
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Vital Signs In Opioid-Exposed Neonates
-
批准号:10493363
-
项目类别:
-
资助金额:$50.77万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
UAB Clinical Site HEAL Neonatal Opioid Withdrawal Pharmacological Treatments
-
批准号:10891299
-
项目类别:
-
资助金额:$22.15万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age
-
批准号:10363406
-
项目类别:
-
资助金额:$148.56万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
UAB Clinical Site HEAL Neonatal Opioid Withdrawal Pharmacological Treatments
-
批准号:10372486
-
项目类别:
-
资助金额:$44.29万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Vital Signs In Opioid-Exposed Neonates
-
批准号:10360908
-
项目类别:
-
资助金额:$51.99万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age
-
批准号:10541156
-
项目类别:
-
资助金额:$152.13万
-
财政年份:2021
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Acute Renal Injury Sequelae in NICU Graduates (ARISING)
-
批准号:9899244
-
项目类别:
-
资助金额:$35.71万
-
财政年份:2019
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Pre-Vent Apnea
-
批准号:10006023
-
项目类别:
-
资助金额:$53.71万
-
财政年份:2016
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Pre-Vent Apnea
-
批准号:9762173
-
项目类别:
-
资助金额:$56.38万
-
财政年份:2016
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Pre-Vent Apnea
-
批准号:9168075
-
项目类别:
-
资助金额:$19.53万
-
财政年份:2016
-
负责人:Namasivayam Ambalavanan
-
依托单位:
STOP BPD
-
批准号:9292368
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2015
-
负责人:Namasivayam Ambalavanan
-
依托单位:
STOP BPD
-
批准号:9143795
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2015
-
负责人:Namasivayam Ambalavanan
-
依托单位:
STOP BPD
-
批准号:8996355
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2015
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Alveolar DevMAP
-
批准号:9062496
-
项目类别:
-
资助金额:$73.48万
-
财政年份:2014
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Alveolar DevMAP
-
批准号:8685690
-
项目类别:
-
资助金额:$74.01万
-
财政年份:2014
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Alveolar DevMAP
-
批准号:8870421
-
项目类别:
-
资助金额:$73.5万
-
财政年份:2014
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Azithromycin to prevent BPD in ureaplasma-infected preterms.
-
批准号:8240026
-
项目类别:
-
资助金额:$59.75万
-
财政年份:2011
-
负责人:Namasivayam Ambalavanan
-
依托单位:
Azithromycin to prevent BPD in ureaplasma-infected preterms.
-
批准号:8610334
-
项目类别:
-
资助金额:$57.19万
-
财政年份:2011
-
负责人:Namasivayam Ambalavanan
-
依托单位:
海外基金